Cempra (CEMP) Stock Soars on Solithromycin Results

Shares of Cempra Inc. (CEMP) were trading up +6.60 or +28.83 percent to $29.49 per share in Monday’s premarket. The company announced on January 4th that its lead product, solithromycin, had positive results in clinical trials. Cempra stock closed at $22.89 per share, down -0.62 or -2.64 percent in Friday’s regular trading session. Chapel Hill, Read the full article... Read the rest of Cempra (CEMP) Stock Soars on Solithromycin Results at InvestorGuide.com .